A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Subject: Multiple Sclerosis - PUBLISHED VIA Neurological Research
Author(s):
Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z
View Source >>
(Price: $54)
Related Studies:
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Published via Expert Review of Neurotherapeutics
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Published via Journal of Neurology
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Published via Expert Review of Neurotherapeutics
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Published via Clinical Therapeutics
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Published via Neurobiology of Disease
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Published via Expert Opinion on Biological Therapy